Trial Profile
An open label, prospective study to evaluate the pharmacokinetics and the safety of odanacatib in healthy male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck & Co
- 09 Dec 2015 New trial record